Drug General Information (ID: DDI7UGYZCP)
Drug Name			Insulin degludec		Drug Info		Ertugliflozin		Drug Info
Drug Type		Hormones				Small molecule
Therapeutic Class		Insulin/Antidiabetic Agents				Antidiabetic Agents
Structure

Mechanism of Insulin degludec-Ertugliflozin Interaction (Severity Level: Moderate)
Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph
Drug Name		Insulin degludec				Ertugliflozin
Mechanism		Hypoglycemic effects				Hypoglycemic effects
Key Mechanism Factor 1
		Factor Name		Hypoglycemia
		Factor Description		Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating.
Mechanism Description		Increased risk of hypoglycemia by the combination of Insulin degludec and Ertugliflozin

Recommended Action
Management		A lower dosage of the insulin secretagogue or insulin may be required when used in combination with an SGLT-2 inhibitor.

References
1	Product Information. Invokana (canagliflozin). Janssen Pharmaceuticals, Titusville, NJ.
2	Product Information. Jardiance (empagliflozin). Boehringer Ingelheim, Ridgefield, CT.
3	Product Information. Steglatro (ertugliflozin). Merck &amp Company Inc, Whitehouse Station, NJ.